Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA Phase 3 Study of Garetosmab in Fibrodysplasia Ossificans Progressiva
jRCT2041220096Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of garetosmab in fibrodysplasia ossificans progressiva (FOP) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Number of new heterotopic ossification (HO) lesions and Incidence and severity of treatment-emergent adverse events of special interest (AESIs). Started Jan 2023; status: active, not recruiting.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on jRCT2041220096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220096.